| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 15
| Issue : 1 | Page : 24-29 |
|
|
Outcome of Radioiodine Therapy in a West African Population
Yetunde A Onimode1, Alfred Ankrah2, Kayode S Adedapo3
1 Department of Nuclear Medicine, University College Hospital; Department of Radiotherapy, University of Ibadan, Ibadan, Oyo State, Nigeria
2 Department of Nuclear Medicine, National Centre for Radiotherapy and Nuclear Medicine, Korle Bu Hospital, Accra, Ghana
3 Department of Nuclear Medicine, University College Hospital, Chemical Pathology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria
Correspondence Address:
Yetunde A Onimode
Department of Nuclear Medicine, University College Hospital, P.M.B. 5116, Mokola, Oyo State
Nigeria
  | Check |
DOI: 10.4103/1450-1147.167585 PMID: 26912975 
|
|
|
Hyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nigeria. This is a retrospective analysis of consecutive patients treated with RAI for primary hyperthyroidism at the National Centre for Radiotherapy and Nuclear Medicine (NCRNM) from 2008-2013, and in the University College Hospital (UCH) from 2006-2013. Cure was defined as euthyroidism or hypothyroidism occurring at 6 months post-RAI. Data were analysed using SPSS version 21 and Epi Info version, categorical data were evaluated with the Chi-square test and Fisher's exact test. 94 patients were studied, aged 20-74 years; 78 were females, and 16 were males. 38 were Ghanaian and 56 Nigerian. The presence of thyroid-associated ophthalmopathy (TAO) made cure less likely (χ2 P = 0.006, odds ratio = 0.118; 95% confidence interval, 0.027-0.518). Other factors assessed proved to be insignificant. Our findings suggest that hyperthyroid patients with TAO will benefit from a higher RAI dose than their counterparts without TAO. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Users Online: 558 
